Evaluating the Effect of Longitudinal Dose and INR Data on Maintenance
  Warfarin Dose Predictions
  Warfarin, a commonly prescribed drug to prevent blood clots, has a highly
variable individual response. Determining a maintenance warfarin dose that
achieves a therapeutic blood clotting time, as measured by the international
normalized ratio (INR), is crucial in preventing complications. Machine
learning algorithms are increasingly being used for warfarin dosing; usually,
an initial dose is predicted with clinical and genotype factors, and this dose
is revised after a few days based on previous doses and current INR. Since a
sequence of prior doses and INR better capture the variability in individual
warfarin response, we hypothesized that longitudinal dose response data will
improve maintenance dose predictions. To test this hypothesis, we analyzed a
dataset from the COAG warfarin dosing study, which includes clinical data,
warfarin doses and INR measurements over the study period, and maintenance dose
when therapeutic INR was achieved. Various machine learning regression models
to predict maintenance warfarin dose were trained with clinical factors and
dosing history and INR data as features. Overall, dose revision algorithms with
a single dose and INR achieved comparable performance as the baseline dose
revision algorithm. In contrast, dose revision algorithms with longitudinal
dose and INR data provided maintenance dose predictions that were statistically
significantly much closer to the true maintenance dose. Focusing on the best
performing model, gradient boosting (GB), the proportion of ideal estimated
dose, i.e., defined as within $\pm$20% of the true dose, increased from the
baseline (54.92%) to the GB model with the single (63.11%) and longitudinal
(75.41%) INR. More accurate maintenance dose predictions with longitudinal dose
response data can potentially achieve therapeutic INR faster, reduce
drug-related complications and improve patient outcomes with warfarin therapy.
